文献速递特殊人群用药治疗药物监测与药物基因组学

模型引导法推荐布罗索单抗用于儿童和成人肿瘤性骨软化症的给药方案

Model-Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor-Induced Osteomalacia.
PubMed 文献 · Clin Pharmacol Ther · 2024-10-24

本研究采用模型引导药物开发方法,整合肿瘤性骨软化症与X连锁低磷血症患者数据,建立布罗索单抗药代动力学和药效学模型,模拟支持成人和儿童给药方案。模拟显示儿童每2周0.3和0.4 mg/kg、成人每4周0.3和0.5 mg/kg可实现一定比例患者血磷正常且高磷血症风险较低,基于血磷滴定的给药可提高达标概率。

要点

  • 儿童每2周0.3或0.4 mg/kg稳态时≥30%患者血磷正常,高磷血症风险<3%。
  • 成人每4周0.3或0.5 mg/kg应答比例相似,高磷血症风险<7%。
  • 基于空腹血清磷滴定的给药可提高血磷正常达标概率。

核心结论

  • 模型引导方法支持布罗索单抗基于空腹血磷监测的滴定给药用于成人和儿童肿瘤性骨软化症。

研究设计与样本

  • 模型引导药物开发研究,整合肿瘤性骨软化症与X连锁低磷血症患者数据。
  • 采用一室模型描述药代动力学,S形Emax模型描述药效学关系。
  • 利用最终模型模拟支持成人和儿童给药推荐。

主要发现

  • 体重是布罗索单抗药代动力学的显著协变量。
  • 基线FGF23对基线空腹血磷、布罗索单抗效力和肿瘤性骨软化症疾病状态对药效学有显著影响但无临床意义。
  • 儿童每2周0.3和0.4 mg/kg稳态时≥30%患者血磷正常,高磷血症风险<3%。
  • 成人每4周0.3和0.5 mg/kg应答比例相似,高磷血症风险<7%。
  • 基于血清磷滴定的给药提高血磷正常达标概率。

关键数值与推荐

  • 儿童起始剂量每2周0.3或0.4 mg/kg,稳态时≥30%患者血磷正常,高磷血症风险<3%。
  • 成人每4周0.3或0.5 mg/kg,应答比例相似,高磷血症风险<7%。
  • 滴定给药依据空腹血清磷监测。

临床怎么用

  • 临床可依据空腹血清磷水平滴定布罗索单抗剂量。
  • 儿童可考虑每2周0.3或0.4 mg/kg起始,成人每4周0.3或0.5 mg/kg起始。
  • 治疗中监测血磷以平衡疗效与高磷血症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burosumab is approved for the treatment of hypophosphatemia in persistent tumor-induced osteomalacia. This work exemplifies a model-informed drug development approach that evaluated burosumab pharmacokinetics and pharmacokinetic/pharmacodynamics in the ultrarare tumor-induced osteomalacia population to support adult and pediatric dosing. Data from tumor-induced osteomalacia participants were combined with data from X-linked hypophosphatemia to understand pharmacokinetic and pharmacokinetic/pharmacodynamic characteristics and covariates specific to tumor-induced osteomalacia. Pharmacokinetic and pharmacokinetic/pharmacodynamic simulations were performed using final models to support dosing recommendations for adults and extrapolation to pediatric patients. Burosumab pharmacokinetics were described using a one-compartment model with first-order absorption and body weight as a significant covariate. Pharmacokinetic/pharmacodynamic relationships were described using a sigmoidal Emax model with significant covariates of baseline fibroblast growth factor 23 on baseline fasting serum phosphate and potency of burosumab response and tumor-induced osteomalacia disease state resulting in a steep slope of response; however, the covariates are not clinically meaningful. Simulations demonstrated that, in pediatric patients, starting doses of burosumab 0.3 and 0.4 mg/kg every 2 weeks at steady state would achieve normal serum phosphate levels in ≥ 30% of patients with relatively low risk of hyperphosphatemia (< 3%). In adults, burosumab 0.3 and 0.5 mg/kg every 4 weeks achieves similar percentages of responders and a relative low risk of hyperphosphatemia (< 7%). Serum phosphate titration-based burosumab dosing increased the probability of achieving normal serum phosphate levels. The models supported a model-informed drug development approach for global approvals of titration-based burosumab dosing, guided by monitoring fasting serum phosphate levels.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hruska MW, Sid-Otmane L, Gosselin NH, et al. Model-Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor-Induced Osteomalacia. Clin Pharmacol Ther. 2024. PMID: 39446135. doi:10.1002/cpt.3468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。